Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

Wegovy

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

Lower U.S. prices, intensifying competition, patent expiries prompted the downgrade.

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

Amazon Pharmacy Adds FDA-Approved Wegovy Pill With $25 Copays and Nationwide Delivery

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA-Cleared Wegovy Pill Becomes First Oral GLP-1 for Weight Loss

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

UK Regulator Probes Pancreatitis Cases Linked to GLP-1 Weight-Loss Drugs

Novo Nordisk Launches Wegovy Weight-Loss Drug in India